Drug intelligence / Profile preview

Bifidobacterium

Development stage: Unknown
Lead developer: BIFIDO
Modality: Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration: Oral

Overview

Bifidobacterium is a probiotic biologic being evaluated as a therapeutic intervention for major depressive disorder, particularly in hospitalized adolescents. Investigated by researcher Zhen-Hong Hu, the treatment is typically administered orally in capsule form and often used in combination with high-frequency repetitive transcranial magnetic stimulation (rTMS). The mechanism of action involves modulation of the gut-brain axis, where the bacteria alter the gut microbiota composition, stimulate the production of neurotransmitters such as serotonin, and reduce systemic inflammatory cytokines. Clinical trial data (ISRCTN16752763) indicates that an 8-week regimen of Bifidobacterium combined with rTMS significantly improves depressive symptoms as measured by the HAMD-24 scale.

Other names: bifidobacterium-Zhen-Hong Hu-depressive disorderBifidobacterium probiotic

Targets

IL10 (Interleukin-10)

Beyond the preview

Go deeper on Bifidobacterium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bifidobacterium.

Explore the full profile